Protagonist Therapeutics (PTGX) Tops Q2 EPS by 3c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of ($0.55), $0.03 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $5.55 million versus the consensus estimate of $7.51 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• AMD (AMD) reaches $1 trillion market cap
• Increasing unusual call option volume: EH WU CRDU DC CYPH BWXT DBC BMEA BURL
• Bloom Energy Corp. (BE) call put ratio 1.2 calls to 1 put as share price up 1.2%